FidoCure To Unveil Breakthrough in Canine Hemangiosarcoma at 2024 Veterinary Cancer Society Annual Conference – FidoCure

PALO ALTO, Calif. (October 15, 2024) — FidoCure, a leader in AI-driven precision oncology for dogs, is excited to share landmark findings at the 2024 Veterinary Cancer Society (VCS) Annual Conference. This research, Genetic Alterations Associated with Prognosis and Better Therapeutic Outcomes in Dogs with
Splenic Hemangiosarcoma, marks a significant advancement in the fight against hemangiosarcoma, the most prevalent and deadly cancer in dogs. This presentation highlights FidoCure’s work to connect cutting-edge science with one of the most pressing unmet needs in animal health.

Leave a Reply Cancel reply

DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. Access to therapy is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.

© Copyright 2018-2023 OHC, All rights reserved